SNCA and Parkinson disease: Current brain-related biomarkers of PD are either costly (magnetic resonance imaging, positron emission tomography scans) or invasive; for example, the new alpha-synuclein seed amplification assays require cerebrospinal fluid or skin biopsy tests [7–9].